Z
Zhenxian Zhou
Publications - 9
Citations - 508
Zhenxian Zhou is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 3 publications receiving 460 citations.
Papers
More filters
Journal ArticleDOI
Serum microRNA Profiles Serve as Novel Biomarkers for HBV Infection and Diagnosis of HBV-Positive Hepatocarcinoma
Limin Li,Zhibin Hu,Zhenxian Zhou,Xi Chen,Fenyong Liu,Junfeng Zhang,Hongbing Shen,Chen-Yu Zhang,Ke Zen +8 more
TL;DR: This study demonstrates for the first time that serum miRNA profiles can serve as novel and noninvasive biomarkers for HBV infection and HBV-positive HCC diagnosis.
Journal ArticleDOI
A pilot study of serum microRNA signatures as a novel biomarker for occult hepatitis B virus infection
TL;DR: The hypothesis that OBI patients have a differentially expressed profile of microRNA (miRNA) in serum, and this unique serum miRNA signature can serve as a biomarker to detect OBI is tested.
Journal ArticleDOI
Circulating human cytomegalovirus-encoded HCMV-miR-US4-1 as an indicator for predicting the efficacy of IFNα treatment in chronic hepatitis B patients.
Yi Pan,Nan Wang,Zhenxian Zhou,Hongwei Liang,Chaoyun Pan,Dihan Zhu,Fenyong Liu,Chen-Yu Zhang,Yujing Zhang,Ke Zen +9 more
TL;DR: Serum HCMV-miR-US4-1 can serve as a novel biomarker for predicting the outcome of IFNα treatment in CHB patients and is demonstrated to be a good indicator for interferon α treatment.
Journal ArticleDOI
Cost-Effectiveness of Bevacizumab Biosimilar LY01008 Combined With Chemotherapy as First-Line Treatment for Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small Cell Lung Cancer
Xia Luo,Qiao Liu,Zhenxian Zhou,Lidan Yi,Liubao Peng,Xiaomin Wan,Xiaohui Zeng,Chongqing Tan,Sini Li +8 more
TL;DR: From the perspective of the Chinese healthcare system, first-line LY01008 at a real-world dosage combined with chemotherapy is likely to represent a cost-effective strategy compared with first- line chemotherapy alone for Chinese advanced or recurrent nonsquamous NSCLC patients.
Journal ArticleDOI
The Cost-Effectiveness of Tislelizumab Plus Chemotherapy for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer
TL;DR: For Chinese patients with locally advanced or metastatic nsqNSCLC who had no known sensitizing EGFR mutations or ALK rearrangements, adding the Chinese-developed anti-PD-1 antibody tislelizumab to the first-line pemetrexed-platinum chemotherapy was cost-effective regardless of their baseline characteristics.